These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 26502403)

  • 21. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
    Amiri-Kordestani L; Pazdur R
    Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
    Wagner J; Marquart J; Ruby J; Lammers A; Mailankody S; Kaestner V; Prasad V
    BMJ; 2018 Mar; 360():k668. PubMed ID: 29514787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

  • 26. Beyond fast track for drug approvals.
    Roberts TG; Chabner BA
    N Engl J Med; 2004 Jul; 351(5):501-5. PubMed ID: 15282359
    [No Abstract]   [Full Text] [Related]  

  • 27. The ODAC chronicles: part 1. My first ODAC experience.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):709-12. PubMed ID: 15485306
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey.
    Yu T; Hsu YJ; Fain KM; Boyd CM; Holbrook JT; Puhan MA
    BMJ Open; 2015 Nov; 5(11):e007960. PubMed ID: 26614616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. While We're at It, Let's Whack the FDA.
    Chabner BA
    Oncologist; 2016 Mar; 21(3):259-60. PubMed ID: 26869585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. US Food and Drug Administration approves first cancer treatment for any solid tumors with specific biomarker.
    Cancer; 2017 Oct; 123(19):3652-3653. PubMed ID: 28940329
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.
    Gyawali B; Kesselheim AS
    Nat Rev Clin Oncol; 2021 Jul; 18(7):397-398. PubMed ID: 33767454
    [No Abstract]   [Full Text] [Related]  

  • 33. US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals.
    Hey SP; Kesselheim AS; Patel P; Mehrotra P; Powers JH
    JAMA Intern Med; 2020 Jan; 180(1):131-138. PubMed ID: 31710344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020.
    Miljkovic MD; Tuia JE; Olivier T; Haslam A; Prasad V
    JAMA Intern Med; 2022 Dec; 182(12):1319-1320. PubMed ID: 36315136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Swimming upstream: an advocate reflects on cancer research and social realities.
    Mayer M
    J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190
    [No Abstract]   [Full Text] [Related]  

  • 37. Inappropriate use of progression-free survival in cancer drug approvals.
    Naci H; Davis C
    BMJ; 2020 Mar; 368():m770. PubMed ID: 32156802
    [No Abstract]   [Full Text] [Related]  

  • 38. Many cancer drugs recently approved in US do not improve overall survival, study finds.
    McCarthy M
    BMJ; 2015 Oct; 351():h5634. PubMed ID: 26500344
    [No Abstract]   [Full Text] [Related]  

  • 39. Accelerated approval and oncology drug development timelines.
    Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
    J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
    [No Abstract]   [Full Text] [Related]  

  • 40. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
    Mailankody S; Prasad V
    JAMA Oncol; 2017 Jul; 3(7):889-890. PubMed ID: 27892992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.